|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
63,632,000 |
Market
Cap: |
1.59(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$24.98 - $24.98 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Provention Bio is a biopharmaceutical company. Co.'s pipeline of investigational candidates under development includes: PRV-031 (teplizumab), an anti-CD3 monoclonal antibody (mAb) for the delay of clinical Type 1 Diabetes (T1D); PRV-3279, a bispecific scaffold molecule targeting the B-cell surface proteins, FcgammaRIIb and CD79B, for the treatment of systemic lupus erythematosus; PRV-015 (ordesekimab), an anti-interleukin 15 mAb for the treatment of gluten-free diet non-responsive celiac disease; and PRV-101, a Coxsackie Virus B (CVB) vaccine to prevent acute CVB infections and to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
5,594,666 |
Total Sell Value |
$0 |
$0 |
$0 |
$85,590,128 |
Total People Sold |
0 |
0 |
0 |
4 |
Total Sell Transactions |
0 |
0 |
0 |
13 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ramos Eleanor |
CMO & COO |
|
2019-12-26 |
4 |
B |
$14.34 |
$28,680 |
D/D |
2,000 |
62,000 |
2.74 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2019-12-20 |
4 |
B |
$11.39 |
$23,634 |
D/D |
2,075 |
2,563,000 |
2.81 |
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2019-12-16 |
4 |
B |
$11.92 |
$23,840 |
D/D |
2,000 |
2,553,450 |
2.74 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-12-03 |
4 |
A |
$0.00 |
$0 |
D/D |
342,000 |
520,712 |
|
- |
|
Digiandomenico Anthony |
Director |
|
2019-09-30 |
4 |
B |
$6.83 |
$204,900 |
D/D |
30,000 |
178,712 |
2.39 |
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2019-09-30 |
4 |
B |
$7.67 |
$11,122 |
D/D |
1,450 |
2,551,450 |
2.74 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-09-26 |
4 |
B |
$8.44 |
$42,200 |
D/D |
5,000 |
148,712 |
2.39 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-09-25 |
4 |
B |
$8.39 |
$41,950 |
D/D |
5,000 |
143,712 |
2.39 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2019-09-24 |
4 |
B |
$8.38 |
$25,140 |
D/D |
3,000 |
2,560,925 |
2.81 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-08-08 |
4 |
B |
$9.09 |
$90,900 |
D/D |
10,000 |
138,712 |
2.39 |
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2019-08-08 |
4 |
B |
$9.09 |
$22,725 |
D/D |
2,500 |
2,550,000 |
2.74 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2019-08-08 |
4 |
B |
$9.15 |
$96,990 |
D/D |
10,600 |
2,557,925 |
2.81 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-06-20 |
4 |
B |
$10.96 |
$109,600 |
D/D |
10,000 |
128,712 |
2.39 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2019-06-18 |
4 |
B |
$10.83 |
$43,320 |
D/D |
4,000 |
2,547,325 |
2.81 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-06-18 |
4 |
B |
$10.88 |
$108,800 |
D/D |
10,000 |
118,712 |
2.39 |
- |
|
Digiandomenico Anthony |
Director |
|
2019-06-17 |
4 |
B |
$12.16 |
$304,000 |
D/D |
25,000 |
108,712 |
2.39 |
- |
|
Bluestone Jeffrey |
Director |
|
2019-06-17 |
4 |
S |
$11.93 |
$87,089 |
D/D |
(7,300) |
7,325 |
|
- |
|
Bluestone Jeffrey |
Director |
|
2019-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,625 |
|
- |
|
Leon Francisco |
Chief Scientific Officer |
|
2018-12-31 |
4 |
B |
$1.64 |
$16,400 |
D/D |
10,000 |
2,547,500 |
2.81 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2018-12-31 |
4 |
B |
$1.58 |
$1,304 |
D/D |
825 |
2,543,325 |
2.73 |
- |
|
Pisano Wayne |
Director |
|
2018-12-28 |
4 |
B |
$1.80 |
$9,000 |
D/D |
5,000 |
7,500 |
2.39 |
- |
|
Palmer Ashleigh |
President and CEO |
|
2018-12-28 |
4 |
B |
$1.73 |
$8,650 |
D/D |
5,000 |
2,542,500 |
2.81 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-28 |
4 |
B |
$1.76 |
$17,600 |
D/D |
10,000 |
83,712 |
2.39 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-27 |
4 |
B |
$1.95 |
$39,000 |
D/D |
20,000 |
73,712 |
2.39 |
- |
|
Catlin Avery W |
Director |
|
2018-12-26 |
4 |
B |
$1.85 |
$9,250 |
I/I |
5,000 |
20,000 |
2.1 |
- |
|
94 Records found
|
|
Page 3 of 4 |
|
|